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ysis, logistic analysis, survival analysis, and recursive partitioning decision analy-
sis were used to estimate the relationship between the financial impact of a new
drug indication and the probability of its reimbursement. The multivariable anal-
yses controlled for other clinical and economic variables that have been shown to
be correlatedwith the probability of reimbursement, including the cost per quality-
adjusted life-year gained. RESULTS: In all analyses, financial impact was a signif-
icant predictor of the probability of reimbursement. For example, in the logistic
analysis, the odds ratio of reimbursement for a drug submission with a financial
impact greater than A$10 million compared with A$0 or less was 0.12 (95% confi-
dence interval [CI]: 0.03-0.55); the odds ratio of reimbursement for a drug submis-
sion with a financial impact greater than A$0 up through A$10 million compared
with A$0 or less was 0.16 (95% CI: 0.04-0.60). Similar results were obtained in the
survival analysis. In the recursive partition decision analysis, the first split of the
data was for submissions with a positive financial impact compared with those
with a negative financial impact. CONCLUSIONS: In Australia, financial impact on
the health care system is an important determinant of whether a new drug is
recommended for reimbursement, even when cost-effectiveness estimates and
other clinical and economic variables are controlled.
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ASSESSMENT AND REIMBURSEMENT ANALYSIS IN THE UNITED STATES
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OBJECTIVES: Cellular therapies and regenerativemedicines, are poised to have the
same paradigm-shifting influence on healthcare as monoclonal antibodies (mABs)
and personalizedmedicine.While these therapies hold similarities to conventional
biopharmaceuticals, they also differ in material ways including attributes of both
medical devices and pharmaceuticals; use of multiple procedures to prepare and
deliver cells; and the potential to cure some diseases. Because of their complexity,
these technologies are also anticipated to be costly and face heavy scrutiny of
value. The objective of this research is to evaluate recent reimbursement policies
on regenerative medicines, compare them to current biopharmaceuticals, and
evaluate lessons for health economics and outcomes research (HEOR) and reim-
bursement planning. METHODS: A search of US HTAs from the Centers for Medi-
care and Medicaid Services, the Agency for Healthcare Research and Quality
(AHRQ), the BlueCross BlueShield Technology Evaluation Center and publicly avail-
able commercial payer coverage policieswas conducted to identify reimbursement
recommendations and supporting rationale. A review of the literature, including
the Cochrane Library and PubMed was also conducted using relevant MeSH terms
and text words to identify additional reimbursement issues associated with regen-
erative medicines. RESULTS: Although a nascent treatment area, over 15 technol-
ogy assessments and coverage policies on regenerative medicines were available
from US HTA agencies and payers. Different from most other technologies, some
noncoverage positions have been established prior to the emergence of specific
technologies or supporting evidence. The literature relevant to HEOR issues on
regenerativemedicines is particularly limited to date. CONCLUSIONS:While payer
policies on regenerativemedicines reflected decision factors commonly associated
with biopharmaceuticals, other factors beyond conventional biologics were iden-
tified. These factors include special evidentiary considerations for cell processing
steps, influence of the evidence-base supporting multi-procedural steps on reim-
bursement, and evaluation of the entire procedure vs. the biopharmaceutical
alone. Key considerations for HEOR are discussed.
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OBJECTIVES: The objective of this study was to understand what stakeholders in
US, EU5, Canada & Australia interpret as disease modification. In chronic progres-
sive conditions, disease modification versus symptom control is the ultimate goal
of healthcare specialists. However, there is no consensus on what “disease modi-
fication” really is. From a HTA perspective, not only is there is difficulty in valuing
disease modifying interventions, but also implied risk to payers approving to re-
imburse these drugs at launch.METHODS: Primary research was undertaken with
payers and medical specialists to understand requirements to support disease
modification claims in HTA assessments. Various attributes were assessed during
in-depth discussions and through discrete choice conjoint. Over 100 respondents
were interviewed. RESULTS: The results show that that efficacy is themost impor-
tant attribute considered in disease modification for HTA assessments. The corre-
lation of biomarkers to clinical endpoints also has utility. The market access im-
plications for such products across geographies vary considerably. However, cost-
effectiveness remains a key driver in specific markets. CONCLUSIONS: Disease
modificationmeans delaying or halting the progression of a disease. Efficacy is the
most important single factor, with the evidence of magnitude and duration of
effect both being essential. However, efficacy alone is insufficient to support a
diseasemodification claim. Robust long termdata are also required and data show-
ing a meaningful improvement over currently available therapies. For regulators
and payers, acceptance of a diseasemodification claimmeans that payers take the
risk of reimbursing based on some extrapolation of data at launch. A commitment
to integrate a process of data review of outcomes over time linked with perfor-
mance will ensure any risk is mitigated.
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OBJECTIVES: Vietnam is an emerging pharmaceutical market that is both poorly
understood and undergoing significant change, with a target for introducing uni-
versal healthcare by 2014. The objective of the research was to place Vietnam’s
pricing and reimbursement environment in a context that brings its dynamics into
clearer focus and to gauge the likely future direction of its evolution.METHODS: A
comparison with its neighbour, China, was conducted based on interviews in both
markets with government advisers, health economists and health policy profes-
sors, as well as KOLs. A comparative analysis was then conducted of the market
access dynamics and drivers, as well as of policy reform plans. RESULTS: Many
similarities exist between the P&R environments of the twomarkets, although they
sit at different places along the P&R development continuum. In both, branded
drugs enjoy a considerable price premium over generics, which could be as high as
40 times in Vietnam. However, China is looking to change the situation by remov-
ing the premium for off-patent branded drugs. Despite efforts in to develop their
reimbursement system, direct-sale to hospitals is the primary revenue channel for
pharmaceuticals, with KOL-endorsement amajormarket access driver. In terms of
drug price regulation, the most commonly used measure is through the enforce-
ment of price caps. CONCLUSIONS: The Vietnamese P&R system is similar to that
of China 5-10 years ago. Several fundaments in terms the structure of the health
system, formalisation of the reimbursement system andmarket access drivers are
the same, but China is significantly further down the line than its neighbour. How-
ever, the health reform agendas of the two markets are both heading in similar
directions.
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OBJECTIVES: To present the empirical experience of new drug listing and reim-
bursement under Taiwan’s National Health Insurance (NHI), and to discuss the
performance of such mechanism. We also attempt to assess its impact on the
public access to pharmaceutical innovations. METHODS: The materials are based
on the documentation of Taiwan’sNHIDrug ReviewCommittee (DRC) over 15 years
period (19962010). We defined the criteria of pricing methods into 9 categories:
International Price Comparison, Comparison with Similar Products with Equiva-
lent Therapeutic Effects, Price Proportion Method, Price Addition, Orphan Drugs,
The Lowest Available International Price, Cost Analysis, Grouping and Others in-
cluded risk sharing managements. RESULTS: The total number of new drugs that
applied for NHI listing and reimbursement during 19962010 was 1103, and the
number of petition cases was 587(53%). The total number of new drugs with final
pricing decisions in this study was 802. Among them, 343 items were issued with
reimbursement pricewithout petition, and the remaining new drugs received their
reimbursement prices after petition on initial pricing decisions. The approved price
was averaged 69% of the international median prices, and was only 60% of inter-
national median prices among petition cases. The top threemethods of pricing are
Price Proportion Method, Equivalent Therapeutic Effect with Similar Product
(23.5%), and International Price Comparison. Because NHI faced financial crisis in
the past 10 years, the price of reimbursement came as approximately 70% of their
respective application prices in the recent years. More and more risk-sharing
agreements were introduced in the price negotiation. CONCLUSIONS: The poten-
tial pressure on theNHImay be even greater for growing financial gap in the future.
There are more efforts needed to seek the transparency in the listing and pricing
process for public good.
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OBJECTIVES: Tomeasure willingness to pay (WTP) for a QALY in Korea.METHODS:
A survey questionnaire based on EQ-5D scenarios was developed tomeasure QALY
improvements in Korea. Double bounded dichotomous choice (DBDC) questions
along with an open question were used to elicit WTPs. Each person was asked for
four scenarios chosen from 3-item EQ-5D scenarios ( 1 QALY) and an additional
scenario with live in perfect health for 1 year or die now (1 QALY). The sameWTP
questions were also repeated for QALY improvements of a family member instead
of self. The questionnaire also includedquestions ondemographics, disease status,
and a visual analog scale (VAS)measure of each scenario presented. Consistency of
each respondent was checked by matching ranks of five scenarios between WTPs
andQALY improvements either by VAS or Korean EQ-5D tariff. Initial bids for DBDC
questionswere determined by the quintiles of pilot surveyWTPs. Survey questions
for each study were fine tuned though two focus group interview sessions per
study. A general population sample was interviewed face-to-face in 2010.
RESULTS:Of the total 1,017 persons surveyed, 933 persons passed consistency test.
For those who passed consistency and not in Medical Aids program, WTP for a
QALY calculated from the final open questions (after DBDC questions) was 19 mil-
lion KRW (approximately 16,000 USD). WTP for family member were consistently
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higher than self. Using DBDC questions seems to have additional benefit of refining
open ended questions. These results were higher especially in parametric estima-
tionmodels using only DBDC questions. This observation cautions us of selecting a
specific analytic method may influence the results. CONCLUSIONS: This study is
the first step toward resolution of controversies around economic evaluations of
healthcare in Korea and hopes to encourage more local research on this issue.
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OBJECTIVES: Preventable hospitalizations (PHs) are hospitalizations that can be
avoided with appropriate and timely access to primary care. Lack of health insur-
ance has been associated with frequent PHs in several communities in the U.S. In
Harris County, public and private safety net clinics provide subsidized primary care
to uninsured individuals. Therefore, being uninsured may not result in unneces-
sary hospitalizations. The objective of this study was to determine the prevalence
of PHs and to examine the effect of health insurance on the risk of PHs in Harris
County (Houston), Texas.METHODS:This studywas restricted to non-elderly adult
(age 18 to 64) residents of Harris County, Texas. The Agency of Healthcare Research
and Quality (AHRQ) guidelines were used to identify a hospitalization as prevent-
able or not from the Texas Health Care Information Collection inpatient discharge
data – 2007. Prevalence wasmeasured as the rate of PHs; i.e. the number of PHs per
100 hospitalizations. Health insurance status was classified as “uninsured”, “Med-
icaid-insured” or “privately-insured”. A 2-analysis followed by a multivariable
logistic regression controlling for demographic and socioeconomic characteristics
was performed to determine the effect of health insurance on the risk of PHs.
RESULTS: There were 17,810 PHs among non-elderly adults in Harris County in
2007 (PH rate  7.83 PHs per 100 hospitalizations). Health insurance status was
significantly associated with PHs (2781.83; p0.001). In themultivariable model,
the uninsured had 60% higher odds of having a PH (OR1.628; p0.001) as com-
pared to the privately insured. Medicaid-insurance was also associated with a
marginally higher risk of PHs (OR1.065; p0.05). CONCLUSIONS: Lack of health
insurance is an important factor in determining risk of PHs in Harris County, de-
spite the presence of safety net clinics. If recent healthcare reforms are successful
in increasing health insurance coverage, a large proportion of these unnecessary
hospitalizations may be avoided.
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OBJECTIVES: To assess impact of the Medicare Part D coverage gap on prescription
drug utilization andmedication adherence using data fromMedicare beneficiaries
enrolled in a large health plan in New Mexico in 2007. METHODS: Quasi-experi-
mental, retrospective, pre-post with control group study design was utilized. Pre-
and post-coverage gap prescription drug utilization and medication adherence of
beneficiaries enrolled in a health plan with no prescription drug coverage during
the coverage gap (no coverage plan) was compared with generic drug coverage
(generic coverage plan) and full prescription drug coverage (full coverage plan) plan
beneficiaries. Prescription drug utilization was assessed using total number of pre-
scriptions per member. Medication adherence was measured using Medication
Possession Ratio and the Proportion of Days Covered (PDC). Difference-in differ-
ence analysis (DiD) was used to compare pre- and post-coverage gap prescrip-
tion drug utilization and medication adherence between the three plans.
RESULTS: Of the 14,846 beneficiaries who met inclusion and exclusion criteria,
2,661 (17.92%) entered the coverage gap in 2007. DiD analyses indicated that
beneficiaries in the no coverage plan filled significantly fewer prescriptions in
the post-coverage gap period, than beneficiaries in the full (14.67 fewer prescrip-
tions; p0.001) and generic (12.52 fewer prescriptions; p0.001) coverage plans.
Significant decrease in post-coverage gap medication adherence was observed
between no coverage and full coverage plan beneficiaries with respect to statins
(5.8%), ARBs (16%) and PPIs (18.1%). Significant decrease in post-coverage gap
medication adherence was observed between no coverage and generic coverage
plan beneficiaries utilizing statins (1.1%) and ARB’s (12%). No significant differ-
ences were observed between full and generic coverage plan beneficiaries. Sig-
nificant differences in adherence were found only when adherence was mea-
sured using the PDC. CONCLUSIONS: Lack of prescription drug coverage during
the Medicare Part D coverage gap may lead to decreased utilization and adher-
ence to certain classes of prescription drugs.
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OBJECTIVES: The aim of the study was to evaluate the quality of pharmacoeco-
nomic studies based in India.METHODS: A literature search was conducted using
PubMed, Medline, EconLit, PsycInfo and Google Scholar to identify published work
on pharmacoeconomics studies based in India. Original research studies that eval-
uated pharmaceuticals, and were conducted between 1990 and 2010 in India were
included. Two reviewers independently reviewed the articles using a subjective
10-point scale (10 being the highest) and the 100-point ‘Quality of Health Economic
Studies’ (QHES) questionnaire (100 being the highest). RESULTS: The included ar-
ticles (n29) were published in 23 different journals. Only 9 articles were published
in journals based in India. The first article was published in 1998. Each article was
written by an average of five authors. Themajority of authors resided in India (62%)
at the time of publication and had a medical background (90%). Cost-effectiveness
analysis was the most frequently used method of analysis (79%). The source of
funding and study perspective was not listed in 45% and 41% of the studies respec-
tively. The study design was a randomized controlled trial for 41% of the studies.
The mean subjective quality score of all the articles (n  29) was 7.8 (SD1.3) and
the mean QHES scores for the studies evaluating costs and outcomes (n  24) was
86 (SD6). The quality score was significantly (p0.05) related to country of resi-
dence of primary author (non-Indiahigher) and the study design (randomized
controlled trialshigher). CONCLUSIONS: The need for economic evaluation of
pharmaceuticals is imperative, especially in developing countries like India; be-
cause it can help decisionmakers allocate scarce resources in a justifiablemanner.
Standardization of guidelines, and improved pharmacoeconomic education -start-
ing from the undergraduate level to specialization - are two suggestions to help to
improve the quality of the pharmacoeconomic research in India.
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OBJECTIVES: To understand the extent of likely variation if any in underlying
relative efficacy and relative effectiveness of drugs used in one or more of the 27
Member States (MS). METHODS: A systematic literature review of studies in four
databases was conducted for the period January 2000 - May 2010: Medline, Embase,
EconLit and Health Management Information Consortium (HMIC). Logical combi-
nations of keywords related to effectiveness, generalisability, external validity,
transferability, Europe and review were searched. RESULTS: A total of 326 articles
were initially identified and ten formed the bases of the review. Nine were
reviews or original cost-effectiveness studies and relevant data on the effective-
ness results was extracted. First, we found that there is a common assumption
in the literature that relative efficacy is constant across countries and therefore
generalisable. Less is known about whether relative effectiveness is indeed
similar or different. Second, we grouped the factors that could potentially in-
troduce variation in relative effectiveness: (i) patients and disease characteris-
tics; (ii) comparators used; (iii) different measures of health outcomes; (iv) vari-
ations in clinical practice. Third, no observational studies were identified.
Evidence from studies using efficacy data, mainly from RCTs, was mixed; three
studies found no differences in clinical outcomes across countries, one study
found differences due to patients’ characteristics and severity and another
study using multilevel analysis found country and patients characteristics ex-
plaining partly the heterogeneity of treatment effects. One review report differ-
ences in clinical practice as one major causes of variations in clinical outcomes
between countries. CONCLUSIONS: The literature was scarce and therefore
more evidence is needed before any statement can be claimed on the existence
of variations in relative effectiveness or efficacy in different countries. Future
collaboration among the MS harmonising methodology, generating data and
sharing patients’ registry data will be crucial to produce this evidence.
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CLINICAL TRIAL LEARNING CURVES AFFECT OUTCOMES MEASUREMENT,
PATIENT SAFETY AND TRIAL SUCCESS: CONTRIBUTING FACTORS AND A
POTENTIAL SOLUTION IN CLINICAL TRIAL SIMULATION
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Taekman JM2
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OBJECTIVES: Evidence has recently emerged regarding the presence of investigator
learning curves in the context of clinical trials (i.e., the association between clinical
protocol departures and patient enrollment sequence). We reviewed the literature
to identify factors contributing to clinical trial learning curves and potential im-
pacts of learning curves on outcomes accuracy, patient safety and overall trial
success. METHODS: The PubMed database was searched for studies describing
clinical trial learning curve effects and potential solutions to these effects, using
search term combinations including “clinical trial”, “clinical protocol”, “learning
curve”, and “enrollment sequence”. RESULTS: Learning curve effects were identi-
fied in trials including those for treatment of sepsis (PROWESS and ADDRESS) and
high-risk cardiac disease (VALIANT). Outcomes of these trials potentially resulting
from learning curves included ambiguous treatment benefit, increased adverse
events andmortality, and overall trial failure. Potential contributing factors include
those related to study site (e.g., large multicenter trials; sites with poor enrollment
or previous trial experience; inexperienced staff and high staff turnover), study
protocols (e.g., imprecise or complex protocols), and disease severity. Preventing
such learning curve effects would likely have required extensive trial site and staff
screening and training, as well as improved trial protocol design prior to first pa-
tient enrollment. Clinical trial simulation, a methodology identified in several re-
ports, could potentially address clinical trial learning curves by improving protocol
design and staff competence. This approach, which focuses on human factors
involved in conducting clinical protocols, offers the potential to improve the accu-
racy of measured trial outcomes and decrease the likelihood of premature trial
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